直近一年間の累計
アクセス数 : ?
ダウンロード数 : ?
ID 116819
著者
Iwatsuki, N Sakamoto Hospital
板東, 浩 Sakamoto Hospital|Tokushima University KAKEN研究者をさがす
Okada, M Sakamoto Hospital
キーワード
Oral hypoglycemic agents (OHAs)
Imeglimin
type 2 diabetes mellitus (T2DM)
Glucose-stimulated insulin secretion (GSIS)
Treatment-emergent adverse events (TEAEs)
American Diabetes Association (ADA)
資料タイプ
学術雑誌論文
抄録
Latest Standards of Medical Care in Diabetes was presented in January 2022. Among oral hypoglycemic agents (OHAs), imeglimin has been topic for a novel agent for type 2 diabetes mellitus (T2DM). Pharmacologically, imeglimin is a cyclic molecule including triazine ring. It has both pharmacological mechanism of increased insulin action and elevation of glucose-stimulated insulin secretion (GSIS). Clinically, it showed HbA1c reduction for 0.46% by monotherapy and 0.56-0.92% by combined therapy with other OHAs. From compared administration of 500mg, 1000mg and 1500mg, 1000mg twice doses would be adequate. No remarkable treatment-emergent adverse events (TEAEs) were found for treatment of imeglimin.
掲載誌名
SunText Review of Pharmaceutical Sciences
ISSN
27665232
出版者
SunText Reviews
3
1
開始ページ
113
発行日
2022-01-23
権利情報
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
医学系